Skip to main content
Premium Trial:

Request an Annual Quote

Indiana Future Fund, Frost & Sullivan, BioTrove, CombiMatrix


Indiana BioCrossroads Fund Invests $73M; Part goes to Life Sciences

The Indiana Future Fund, a $73 million “fund of funds,” has invested a portion of its funds in four life sciences venture capital firms with offices in Indiana. The funds from this round are intended to be invested in Indiana-based life sciences companies.

The parties did not disclose the specific amount of the investment.

The Future Fund made the investments in REI, a joint venture of Rose-Hulman Ventures and EDF Ventures, both of which have offices in Terre Haute, Ind.; Pearl Street Venture Funds; A.M. Pappas & Associates; and Burrill & Company.

The Indiana Future Fund was assembled by BioCrossroads, an organization to promote life sciences investment in Indiana, and includes investments from the state’s pension funds, Eli Lilly, Anthem Blue Cross and Blue Shield; Indiana University, Indiana University Foundation, Purdue University, Ball State University Foundation; American United Life Insurance Company, Indiana State University Foundation and Guidant Corporation.

BioCrossroads, a public-private consortium of life science institutions from central Indiana, in February established a protein center of excellence, called the Indiana Centers for Applied Protein Sciences, that is headed up by James Ludwig, head of proteomics programs at Lilly (see PM 2-20-04).

Frost & Sullivan: Life Science Mass Spec Market Will Reach $1.4B by 2010

Market research firm Frost & Sullivan this week released a report entitled “World Life Science Mass Spectrometry Markets,” which estimated last year’s life science mass spec revenues at a total of $880 million, and predicted that this number would reach $1.4 billion by 2010.

The report pointed to the growth of proteomics, metabolomics, and pharmacokinetics as driving factors for the market, and said that academic institutes channeling more funds into the purchase of mass spec equipment were becoming of greater importance in helping the market to grow.

BioTrove Takes in $13.7M in Financing

Woburn, Mass.-based biochip maker BioTrove announced this week that it had completed a $13.7 million financing round with the close of a $2.8 million second traunch.

Leading the round was Catalyst Health and Technology Partners, with other investors including Echelon Ventures, Fletcher Spaght, CB Health Ventures, Zero Stage Capital, and BioFrontier Partners.

The company will use the funds to accelerate commercialization of its Living Chip and Momentum Assay Development and Screening platforms, and to build a new 10,000 square-foot manufacturing facility.

CombiMatrix collects $13.6M From Direct Share Offering

Acacia Research closed a three-million share offering of common stock in its CombiMatrix life sciences unit, the Newport Beach, Calif.-based company announced this week.

The registered direct offering was to a group of undisclosed institutional investors. The offering was priced at $5 a share, the company said, discounted against the CombiMatrix closing price of $5.53 on Tues., April 13. The offering is expected to raise some $13.6 million for Acacia's Mulkiteo, Wash., subsidiary that is commercializing a microarray technology platform.

The announcement follows CombiMatrix's move from listing on Nasdaq's small-cap market to its big board in March, joining Acacia's other division, Acacia Research/Acacia Technologies, which began trading on the Nasdaq Exchange in December 2002.


The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.